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Abstract 
The outer domain of gp120 is a relatively stable domain compared to the inner domain and bridging sheet at the CD4-binding site 
for the HIV-1 primary receptor.  Therefore, the outer domain has been considered as an immunogen candidate for vaccine design. 
In this report, we focused on the VRC01 antibody binding epitope in the outer domain and evaluated the effects of introducing two 
disulfides to further stabilize the outer domain structure where the antibody binds for the purpose of generating a more effective 
immunogen. Our experimental data based on neutralization activities against HIV-1 of anti-sera produced from immunized guinea 
pigs demonstrated that this stabilized outer domain-based immunogen significantly enhances the specific immune response when 
compared to its wild-type outer domain counterpart. These findings strongly suggest that this structure-based designed epitope is 
effective in eliciting specific neutralizing antibodies against diverse HIV-1strains, including subtype C. 
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1. Introduction 
 
Human immunodeficiency virus type 1 (HIV-1) subtype C is the major epidemic subtype in Africa and Asia, 
and is responsible for about 60% of total HIV-1 infections worldwide1.  Therefore, developing a preventive vaccine,  
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especially one against subtype C, is extremely important for control of the AIDS pandemic.  
Despite numerous efforts made globally in the search for an effective prophylactic vaccine, there has been limited 
success2, and substantial challenges still remain3,4,5.  Lessons from past scientific efforts indicate that traditional or 
conventional vaccine approaches using viral particles or subunits as vaccines will not be effective against HIV-1. 
Therefore, alternative strategies involving more rational or more sophisticated structure-based design of the antigen is 
required for HIV-1vaccine development2,6-9.   
Recently, the identification of several potent neutralizing antibodies from large-scale antibody screening of HIV-1 
patient sera has brought new insight for antibody-based HIV-1 vaccine design10-14. For instance, the newly identified 
CD4-binding site (CD4-BS) antibody VRC01 is able to neutralize 90% of circulating HIV-1 isolates11-13.  This has 
provided evidence that potent and broadly neutralizing antibodies can be generated in vivo. More importantly, as 
delineated from the high resolution structure of the binding complex of gp120 and VRC01 antibody12, the binding site 
of VRC01 antibody is mostly on the outer domain (OD) of gp120, unlike the HIV-1 primary receptor CD4 for which 
the binding site is composed of three domains: outer domain, inner domain and the bridging sheet15,16. This gp120 
outer-domain-only binding characteristic of VRC01 antibody has provided a promising epitope to be targeted for 
vaccine design12. Among the three-domains of the CD4-BS, the outer domain is much more structurally stable than 
the inner domain and bridging-sheet15-18. More recently, the crystal structure of another CD4-BS monoclonal antibody 
(PGV04, also called VRC-PG04) in complex with only the outer domain of gp120 has been reported, demonstrating 
that this potent neutralizing antibody PGV04 is also able to bind to the outer domain independently19. The antigenic 
nature of the CD4-BS has been recognized as conformation dependent because it is known to be located at the junction 
of three domains. Interestingly, the binding sites of CD4-BS antibodies such as VRC01 and PGV04 are actually located 
on the outer domain, and are more independent from both the inner domain and the bridging sheet. Therefore, the outer 
domain of gp120 has been a focused target as an effective vaccine immunogen.  
The first report of using the outer domain of gp120 as an immunogen was in 2004, and showed that the outer domain 
did elicit an immune response, but it did not show better immunogenicity than the whole gp120 molecule20. More 
recent reports using the outer domain as an immunogen included the use of subtype C strain CN5421,22, the non-
glycosylated outer domain molecule23, the membrane-anchored outer domain24, and the outer domain with varying 
lengths of V3-loop25. All these studies suggested that the outer domain of gp120 is a poor immunogen; and also 
indicated that the moderate immune response was elicited mainly against the V3-loop of the outer domain. However, 
these previous studies did not take into consideration the need for further stabilization in order to make an effective 
outer-domain immunogen. 
Our study here was based on the recently obtained structural data of HIV-1 envelope gp120 in complex with its 
broadly neutralizing antibodies12,19. Our findings support the hypothesis that the stabilized gp120 outer domain 
provides  a better immunogen, giving hope for future studies on the outer domain for development of a more effective 
vaccine against multiple HIV-1 strains including subtype C.  
 
2. Materials and methods 
 
2.1 Molecular modeling and designing of OD1 and OD2 
 
The gp120 structure of HIV-1 subtype C strain 1084i was predicted based on the HIV-1 subtype B strain gp120-
VRC01 structure complex (PDB: 3NGB)12. The OD1 and OD2 structures were predicted using Discovery Studio 
Client 3.5 (Accelrys, San Diego, CA). All other structure modeling and disulfides design (see Fig. 1) were also 
performed on this platform of Discovery Studio Client. The protein sequence numbering of OD1 and OD2 is based on 
the envelope sequence of HIV-1 prototypic HXBc2 strain27.  
 
2.2   Cloning and expression of OD1 and OD2 
 
The two designed genes of OD1 (214aa, from 246 to 460 of gp120 1084i strain26, with a 6xHis-tag at the N-
terminus) and OD2 (4 cysteine substitutions in OD1) were synthesized by GenScript, and were cloned into pET28b 
expression vector (Novagen) for protein expression in the E. coli BL21 (DE3) system.  The sequences  of the  cloned  
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Fig.1. Structural models of designed HIV-1 outer domain-based immunogens. (a) The wild-type outer domain (OD1). (b) The stabilized OD2 
immunogen with two introduced disulfides T/C257-G/C472 and E/C370-N/C425.  The 1084i gp120 structure was predicted from the HIV-1 
gp120 structure (PDB: 3NGB) using program Modeler version 9.0 in Discovery Studio (Accelrys, San Diego, CA). 
 
genes were confirmed by DNA sequencing to ensure that the coding region was in frame with the N- and C-terminal 
histidine tag. To express the recombinant proteins, E. coli BL21(DE3) cells were transformed with the plasmid pET28-
OD1 or OD2 and a single colony was grown overnight in LB media supplemented with kanamycin (50mg/L) at 37°C 
until the optical density (OD) reached between 0.4 and 0.6 at 600 nm. The cells were then induced by adding isopropyl-
D-thiogalactopyranoside (IPTG) at a final concentration of 1mM and were further incubated for 4 hrs at 37°C. The 
cells were then harvested by centrifugation at 5000g for 10 min, washed once with STE buffer (100mM NaCl, 10mM 
Tris, and 1mM EDTA, pH 7.5) and finally resuspended in STE buffer containing 0.5% NP40, lysozyme (100mg/L) 
and supplemented with protease inhibitors. After incubation for 30 min at 4°C, the resuspended cells were disrupted 
by sonication and the lysate was centrifuged (12,000g, 10 min, 4°C) to separate the insolubilized fraction. Both 
supernatant and the insolubilized pellet fraction were tested for the presence of recombinant proteins by running on a 
SDS-PAGE followed by Coomassie blue staining. The majority of the expressed protein was detected in insolubilized 
fraction inclusion bodies. The insoluble fraction was further purified by sequentially washing with 1x PBS containing 
2M urea, 0.1% SDS, 1% NP-40 and 1% TritonX-100. The majority of the insoluble fraction after extensive washing 
contained OD1 and OD2. The purified protein was solubilized in solubilization buffer (50mM NaCl, 25mM Tris (pH-
8.0), 2mM EDTA, 8M Urea and 5mM DTT) and was renatured by successive dialysis against refolding buffer (50mM 
Tris, pH 8.0, 400mM L-Arginine, 2mM EDTA, 10mM DTT and 10% glycerol) containing 4, 2, 1 and 0 M Urea at 4 
°C. The protein concentrations were determined using a BCA protein kit (Pierce, Rockford, IL) and the purity of the 
resulting protein was evaluated by Coomassie blue staining and Western blot analysis with anti-His antibody following 
SDS-PAGE. The purified recombinant proteins were used for immunization in Guinea pigs. 
 
2.3    Immunoblotting 
 
For immunoblotting, equal amounts of purified recombinant proteins were separated on a 10% SDS-PAGE and 
subsequently transferred to nitrocellulose membrane using standard methods. After blocking with 5% non-fat dry milk 
in phosphate-buffered saline (PBS) containing 0.01% Tween-20 for 1 hr, the membrane was incubated overnight at 
4°C with primary antibody. Following washing with PBS+0.01% Tween-20, the membrane was incubated with horse 
radish peroxidase (HRP) conjugated goat anti-rabbit/mouse secondary antibody (1:10000, Pierce) or infrared-tagged 
secondary antibodies (1:10000, Licor Inc., Lincoln, NE) for 30 min. Antibody binding was detected using SuperSignal 
West Dura Extended Duration Substrate kit (Pierce) or using an Odyssey imager. Image analysis and quantification 
of immunoreactive bands was performed using the Odyssey Infrared Imaging System application software (LiCor Inc., 
Lincoln, NE). 
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2.4    Mass spectrometry 
 
The specific band of OD2 from the Coomassie blue gel was excised and digested with trypsin in the presence or 
absence of DTT (100 mM) at 37°C. The ProteoProfile™ Trypsin In-Gel Digest Kit (Sigma-Aldrich) was used 
following the suggested protocol. At a specified time period of incubation for 12, 24, and 40 hrs, the samples were 
withdrawn and peptides were purified with ZipTip C18 (EMD Millipore) for MALDI-TOF MS-based finger-print 
analysis, similar to the method as described in previous reports28-30. The final mass spectrum was acquired on an 
AutoFlex (Bruker, Germany) with accumulation of 30 qualified spectra with each of 100 laser shots. The system was 
calibrated externally each time before carrying out the sample analysis. Only qualified spectrum (resolution> 2000) 
was allowed to be added into the final spectrum. Peptide mapping was performed with Paw software. The peak 
differences between two spectra obtained with or without DDT were compared, and the peaks were matched by the 
predicted m/z in both reduced and oxidized digestion conditions. 
 
2.5    Guinea pig immunizations 
 
Blood samples were collected from all guinea pigs on Day 0, prior to immunization. Four booster injections were 
carried out after the first injection. Blood samples were collected four times (2 test bleeds and 2 production bleeds) for 
use in antibody testing and neutralization assay. All animal experiments were performed according to the protocol 
approved by the IACUC of Cocalico Biologicals, Inc. (CBI) (Reamstown, PA). The standard 56-day immunization 
protocol of CBI for guinea pigs was followed.  
 
2.6     ELISA 
 
96-well, flat-bottom, black-sided plates (Grenier Bio-One) were coated with 100 ng per well of test protein diluted 
in coating buffer (15mM Na2CO3 (Sigma-Aldrich) and 35mM NaHCO3, pH 9.6). Prior to blocking, plates were washed 
3x with PBS-T wash buffer (phosphate buffered saline with 0.1% Tween-20 (Sigma-Aldrich)). Plates were blocked 
with 200μL/well blocking buffer (PBS-T with 5% milk) at room temperature (RT) for 2 hrs. After 3 washes, 
100μL/well of guinea pig sera diluted in PBS-T with 0.1% BSA (BioWORLD) was added and incubated at RT for 2 
hrs. Plates were washed 5x prior to addition of 100μL/well of HRP-conjugated goat anti-guinea pig IgG secondary 
antibody (Jackson ImmunoResearch Laboratories Inc.), and incubated at RT for 2 hrs. Plates were washed 5x and 
100μL/well SureBlue ReserveTM TMB substrate (KPL) was added and incubated for 1 min in the dark. To stop the 
reaction, 100μL/well of 1N HCl was added, and absorbance at 450nm was read using an ELX 800 UV universal 
microplate reader (Bio-Tek Instruments). 
 
2.7     Generation and titration of viral stocks 
 
Pseudotyped HIV was produced by transfection into 293T cells grown at 37°C wtih 5% CO2, and maintained in 
DMEM medium with 4.5g/L D-glucose and 584mg/L L-Glutamine (Gibco), supplemented with 10% FBS and 1X 
penicillin-streptomycin. Twenty-four hrs prior to transfection, 1.5x106 cells were plated in 10 cm dishes coated with 
0.01% Poly-L-lysine (Sigma-Aldrich). Cells were transfected by adding 6μg of replication-deficient HIV plasmid, 
600ng HIV envelope construct, and 18μl Fugene 6 (Promega) diluted in unsupplemented DMEM. Cell supernatants 
were collected at 48 hrs post-transfection, and passed through a 0.45μM syringe tip filter. To titer on TZM-bl cells, 
viral stocks were diluted in four replicate 4-fold dilution series and added to 1.5x104 cells per well in 96-well plates. 
Tat-inducible β-galactosidase was measured at 48 hrs PI, and the Reed-Muench method was used to calculate TCID50 
based on endpoint staining.   
 
2.8     Assay for Neutralizing Antibodies 
 
The neutralization assay was based on methods previously described31,32. TZM-bl cells were incubated at 37°C with 
5% CO2, and maintained in DMEM medium with 4.5g/L D-glucose and 584mg/L L-Glutamine, supplemented with 
10% FBS and 1X penicillin-streptomycin. The day preceding infection, cells were seeded at 1.5x104 per well in  
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Fig. 2. (a)  Immunogen expression and purification in E. coli.  The 25kDa band is the expected outer domain (OD) protein. OD1= wild-type outer 
domain without the major loops (V1V2 and V3). OD2= four cysteines introduced in the OD1 molecule. (b) Characterization of the stabilized OD2 
molecule by Western Blots. After electrophoresis and transfer, blots containing BSA, gp120, OD1, and OD2 were probed with pooled serum from 
HIV-1 positive patients, anti-gp120 polyclonal antibody, VRC01 or b12 anti-CD4-BS monoclonal antibodies, or 2G12 anti-gp120 outer domain 
monoclonal antibody. 
 
96-well plates, flat-bottom, black-sided plates (Grenier Bio-One). In a separate 96-well plate, heat-inactivated guinea 
pig serum was serially diluted to a final volume of 150μL cell growth media, mixed with 50μL cell growth media 
containing 200 TCID50 pseudotyped HIV, and incubated for 1 hr at 37°C with 5% CO2. During this incubation, TZM-
bl growth media was replaced with 50μL media containing 160μg/mL DEAE-Dextran (Sigma-Aldrich) (40μg/mL 
final concentration). The serum-virus mixture was added to cells and incubated at 37°C for 48 hrs. The luciferase assay 
system (Promega) was used to detect Tat-inducible luciferase; luminescence was measured on a Veritas luminometer 
(Turner Biosystems). Percent neutralization was determined by the following equation: (1 – ((test well – cell control 
well) / (virus control well – cell control well))) x 100. Neutralizing antibody titers (IC50) were expressed as the 
reciprocal of the serum dilution needed to reduce the relative light unit (RLU) by 50%.  
 
3 Results 
 
3.1    Structure-based immunogen design 
 
The binding structure of the potent neutralizing monoclonal antibody VRC01 to the CD4-binding site (CD4-BS) of 
gp120 (PDB: 3NGB) has shown that its main contact site is the outer domain (OD) of gp120, which is distinct from 
the gp120-CD4 binding site12. The CD4-BS consists of the junction of three domains of gp120 (outer-domain, inner-
domain and the bridging sheet). Since it is known that the outer-domain of gp120 is relatively more stable as compared 
to the inner domain and the bridging sheet, and there is very little conformational change of the outer-domain during 
CD4 receptor binding, it is therefore likely that VRC01-like neutralizing antibodies could be elicited if the outer-
domain alone is used as immunogen.  
In this study we have chosen to focus on an HIV-1 subtype C strain (1084i) that was originally isolated from Zambia 
for our vaccine design, since subtype C is responsible for over 50% of the new infections world-wide. Molecular 
modeling was first performed to predict the envelope structure of 1084i gp120, based on the structure of subtype B 
strain (PDB: 3NGB)12,33. Using this approach, the outer domain structure of 1084i gp120 envelope was determined 
and is shown in Figure 1a. In order to stabilize the outer domain structure, we introduced two new disulfides into the 
molecule.  One disulfide serves to stabilize the N- and C-termini of the outer domain as they are located closely to the 
antibody VRC01 binding site. The other disulfide was to fix the β20/21 hairpin in the CD4-bound conformation18,34,35, 
which is favorable for VRC01 antibody binding (Fig. 1b). Because this design intended to specifically target the 
VRC01 binding site in the core structure of gp120, all V1V2 loops along with the V3-loop were removed, resulting in 
the elimination of any instability caused by the presence of the loop structures. Our assumption is that this re-designed 
outer-domain (OD2) will present a more rigid and intact epitope for the immune system to elicit VRC01 or VRC01-
like antibodies as compared to non-stabilized (wild-type) outer-domain (OD1).  
b a 
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3.2    Generation and validation of outer domain immunogens 
 
The designed immunogen genes (OD1 and OD2) were synthesized by GenScript and cloned into the pET28b vector 
(Novagen) to express the proteins from a bacterial system (E. coli BL21 (DE3) pLysS cells, Invitrogen). These E. coli 
K12 derivatives contain mutations in both the thioredoxin reductase (trxB) and glutathione reductase (gor) genes, 
which will result in a more oxidizing intracellular environment that mimics the eukaryotic endoplasmic reticulum 
(ER), thereby facilitating proper folding of disulfide-containing proteins.  
The non-glycosylated proteins produced in this E. coli system were evaluated by gel SDS-PAGE, followed by 
coomassie blue staining (Figure 2a). A clear band with the expected molecular weight of 25kDa, representing the outer 
domain proteins of 1084i gp120 was detected, which was also confirmed by Western blot using antibody against His-
tag (Fig. 2a). Larger batches of OD1 and OD2 proteins were then prepared and purified via Ni-column for use in 
immunizations.  After purification, the OD1 and OD2 proteins were further confirmed and characterized by Western 
blot analysis using patients sera, anti-gp120 polyclonal antibody, and gp120 specific monoclonal antibodies such as 
VRC01, b12, and 2G12 (Fig. 2b). The antibody VRC01 showed binding affinity to OD1 and OD2 as expected. Also 
antibody b12 also showed binding activity but appeared to be weaker than VRC01. However, antibody 2G12 which 
was able to bind to gp120 outer domain in a glycan-dependent manner failed to bind to OD1 and OD236,37. This is 
likely due to the lack of post-translational glycosylation of the proteins produced in prokaryotic cells.  
 
3.3     Immunogenicity of designed outer domain immunogens 
 
To evaluate the immunogenicity of OD1 and OD2, we tested them in guinea pigs. Two groups of guinea pigs were 
immunized with either OD1 (control) or OD2 (sample) immunogen. The antisera collected from all immunized guinea 
pigs were first tested by Western blot targeting the same antigens used for immunization, and the serum from each 
immunized animal showed binding activity for both OD1 and OD2 (Fig. 3a).  
Further, antibody titers of day 56 and day 200 (final bleed) samples against the antigens were measured by ELISA 
using purified immunogens (Fig. 3b).  Interestingly, OD2 showed lower antibody titers than OD1 in all sera tested. 
We then tested the  neutralization activities of the sera against a panel of HIV-1 isolates, which included the standard 
test strains from Tier 1 (HXBc2) and Tier2 (YU2, ADA, JRFL, 1084i) viruses representing different HIV-1 subtypes, 
including subtype C38. The neutralization data clearly showed that sera from OD2 immunized animals have much 
greater neutralization activities than those from OD1 (Fig. 4), indicating the presence of more neutralizing antibodies 
in OD2 immunized animals than in OD1. Taken together, these data strongly suggest that the stabilized OD2 
immunogen can elicit more specific neutralizing antibodies in spite of lower overall antibody titers responses in 
comparison to OD1.  
 
 
 
 
 
Fig. 3. (a) Western blot analysis of antisera from immunized guinea pigs. BSA= negative control protein, gp120= positive control protein. OD1= 
wild-type outer domain, OD2= stabilized outer domain.  Note that the band of OD1 is slightly higher than OD2, as OD1 has two His-tags at the N- 
and C-terminals, but OD2 used here has just one His-tag at the C-terminal.  (b) ELISA analysis of antisera from immunized guinea pigs.  Plates 
were coated with either BSA, OD1, or OD2, then probed with dilutions of pre-bleed serum, or day 56 or day200 (final bleeds) immunized serum.  
Experiments were performed in triplicate and graphs represent multiple experiments.    
a b 
12   Jesse Thompson et al. /  Procedia in Vaccinology  9 ( 2015 )  6 – 15 
Fig. 4.  Neutralization assays of antisera from immunized guinea pigs (gp1-4) expressed as reduction in relative luciferase units compared to wells 
in which virus was added with no serum. OD1=wild-type outer domain, OD2=stabilized outer domain.  Subtype B HIV-1 strains: ADA, JRFL, 
YU2 and HXBc2, Subtype C strain: 1084i.  Graphs are representative of 3 independent experiments. 
 
3.4     Verification of introduced disulfides for stabilization 
 
Although OD2 immunization resulted in higher neutralization capacity, presumably due to the introduction of 
disulfide bonds, it is still important for us to demonstrate that these two disulfide-bonds were actually formed in the 
molecule. Based on the design, one disulfide-bond (C257/C472) serves to stabilize the N-terminus with the C-
terminus, while the other (C370/C425) stabilizes the β20/21 hairpin. Consequently, the epitope region recognized by 
the antibody VRC01 should be more rigid and have less flexibility as compared to the non-stabilized structure (Fig. 
1). To verify that the two introduced disulfides result in the formation of disulfide bonds, Mass spectrometry (MS) 
was used. The purified OD2 protein was digested by trypsin with or without dithiothreitol (DTT). Fragments 
containing the introduced disulfide linkages of molecular weight 5431 kDa and 6313 kDa were expected (Fig. 5a). As 
analyzed by MS, these specific disulfide-linked fragments (circled in blue) were identified (Fig. 5b), and the slight 
difference between the predicted and the MS measured molecular weights (MW) could be a result of methods used in 
the calculation between them. This result clearly demonstrated that the two designed disulfide-bonds were formed in 
the OD2 molecule. Thus, the stabilization of the gp120 outer domain by introducing the disulfide-bonds resulted in 
the generation of a higher level of specific neutralizing antibodies upon immunization, as compared to the non-
stabilized wild-type outer domain.   
 
4 Discussion 
 
Recent discoveries of potent neutralizing antibodies such as VRC01 have provided an excellent opportunity for 
antibody epitope structure-based design of HIV-1 vaccines39-41. The rationale for structure-based design is based on 
the notion that an antibody epitope-based antigen used as vaccine can induce similar types of antibodies that bind to 
the same epitope.  
 
 
Fig. 5. Verification of introduced disulfide bonds (two) in the designed immunogen by Mass spectrometry (MS).  (a) The protein sequences and 
molecular weights of predicted disulfide fragments of C13/C202 and C114/C155.  (b) ESI-MS/MS data showing the disulfide-linked tryptic peptides 
(blue circles) in the graphs.  
 
a b 
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Fig. 6. Superimposed structures of predicted OD2 (cyan) and the outer domain structure (PDB: 3SE9) (magenta). 
 
In this report, we have focused on the antibody VRC01 epitope in the outer domain of gp120 to test this possibility. 
This design involved the use of several strategies: 1) keeping the main core structure, 2) removing all the flexible loops 
(V1, V2 and V3), and 3) introducing disulfides to both stabilize the N and C-termini, and to fix the β20/21 hairpin. 
We predicted that these approaches may serve to stabilize the VRC01 epitope by eliminating factors that may lead to 
instability, and keeping the binding site rigid and intact. To this end, we designed an immunogen which is VRC01 
epitope-focused, stabilized, without any major loops, and expressed in E. coli, thus making non-glycosylated. This 
design could potentially amplify the epitope-specific neutralization antibody response while simultaneously 
minimizing non-neutralization responses. Indeed, this uniquely designed immunogen OD2 was shown to increase 
immunogenicity and elicit broadly neutralizing antibody activities, even though the OD2 was found to elicit a lower 
overall antibody titers compared to OD1.   
Although this immunogen excludes the V3-loop or glycan-dependent immunogenicity in general, it largely 
enhanced and concentrated the specificity of immunogenicity on the antibody VRC01 binding epitope. That may be 
the precise explanation as to why this OD2 immunogen was capable of inducing potent neutralizing antibodies against 
different HIV-1 strains, while also minimizing the non-neutralization responses.  
We based our study here on a recent report of the outer domain structure of gp12019, and superimposed it to our 
predicted 1084i gp120 outer domain structure, showing that there are differences in their β20/21 hairpins (Fig. 6). The 
β20/21 hairpin is a part of the bridging sheet at the CD4-binding site, and it is also close to the VRC01 binding epitope. 
It is likely that this local conformational change may contribute to the binding site stabilization and integrity, thus 
affecting the binding of the VRC01 antibody or other VRC01-like antibodies. This observation suggests that further 
stabilization of the outer domain is needed in order to achieve an even more effective immunogen for use as a vaccine 
candidate.  
 
5 Conclusions 
 
The antibody VRC01 epitope-focused and outer domain structure-based design of an HIV-1 vaccine immunogen 
was tested in guinea pigs. Data generated on antibody titers, immunogenicity and neutralizing activity showed that the 
stabilized immunogen OD2 by introduction of disulfide-bonds is more effective than the wild-type OD1 in generating 
neutralizing response and reducing the levels of non-neutralizing antibodies. This study will serve as a base to facilitate 
the development of a more effective HIV-1 vaccine to control the AIDS epidemic.  
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